<DOC>
	<DOCNO>NCT00466609</DOCNO>
	<brief_summary>This control , randomize , double-blind double-dummy study treatment augmentation strategy obsessive compulsive disorder patient non-respondent first line pharmacological treatment . The investigator compare : fluoxetine maintenance maximum dosage additional 12 week ; association fluoxetine quetiapine ; association fluoxetine clomipramine .</brief_summary>
	<brief_title>Using Drug Augmentation Treat Obsessive Compulsive Disorder Patients Who Did Not Respond Previous Treatment</brief_title>
	<detailed_description>Arm 1 : SSRI ( Fluoxetine 40mg* day ) + Clomipramine 75mg* day . Arm 2 : SSRI ( Fluoxetine 40mg* day ) + Quetiapine 200mg* day . Arm 3 : SSRI ( Fluoxetine 80mg* day ) + Placebo day . *or maximum tolerate dose We hypothesize quetiapine clomipramine effective augmentation strategy resistant OCD patient comparison placebo .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Clomipramine</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>1 . OCD diagnosis 2 . YBOCS score ≥ 16 ( patient obsession compulsion ) ≥ 10 ( patient obsession compulsion ) 3 . Previously sign inform consent participate clinical trial 1 . Patients clinical neurological disease may worsen medication include treatment protocol 2 . Current substance dependence abuse 3 . Current psychotic symptom 4 . Current suicide risk 5 . Current pregnancy intention get pregnant end treatment protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>clomipramine</keyword>
	<keyword>quetiapine</keyword>
	<keyword>fluoxetine</keyword>
	<keyword>placebo</keyword>
	<keyword>augmentation</keyword>
	<keyword>obsessive compulsive disorder</keyword>
</DOC>